3/3
08:00 am
rvty
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Low
Report
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
2/20
12:30 pm
rvty
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
Low
Report
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
2/20
08:00 am
rvty
Revvity to Present at Upcoming Investor Conferences
Low
Report
Revvity to Present at Upcoming Investor Conferences
2/3
01:26 pm
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Barclays PLC from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Barclays PLC from $135.00 to $140.00. They now have an "overweight" rating on the stock.
2/3
09:25 am
rvty
Revvity, Inc. (NYSE: RVTY) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $145.00 price target on the stock, up previously from $140.00.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $145.00 price target on the stock, up previously from $140.00.
2/3
08:57 am
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at KeyCorp from $132.00 to $145.00. They now have an "overweight" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at KeyCorp from $132.00 to $145.00. They now have an "overweight" rating on the stock.
1/31
06:00 am
rvty
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
Medium
Report
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
1/23
04:05 pm
rvty
Revvity Board Declares Quarterly Dividend
Low
Report
Revvity Board Declares Quarterly Dividend
1/21
12:46 pm
rvty
Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Raymond James from $146.00 to $140.00. They now have an "outperform" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Raymond James from $146.00 to $140.00. They now have an "outperform" rating on the stock.
1/13
08:00 am
rvty
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
Medium
Report
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
1/12
05:00 pm
rvty
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
Medium
Report
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
1/10
09:03 am
rvty
Revvity, Inc. (NYSE: RVTY) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $130.00 price target on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $130.00 price target on the stock.
1/10
08:00 am
rvty
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
Low
Report
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
12/17
08:00 am
rvty
Revvity to Present at J.P. Morgan Healthcare Conference
Low
Report
Revvity to Present at J.P. Morgan Healthcare Conference